Would you consider donating your left-over embryos to treat Parkinson's disease? Interviews with individuals that underwent IVF in Sweden.
Cryopreserved embryos
Ethical aspects
Human embryonic stem cells
Parkinson’s disease
Qualitative research
Journal
BMC medical ethics
ISSN: 1472-6939
Titre abrégé: BMC Med Ethics
Pays: England
ID NLM: 101088680
Informations de publication
Date de publication:
03 12 2022
03 12 2022
Historique:
received:
09
03
2022
accepted:
23
11
2022
entrez:
3
12
2022
pubmed:
4
12
2022
medline:
7
12
2022
Statut:
epublish
Résumé
Parkinson's disease (PD) has been considered to be one of the most promising target diseases for forthcoming cell-based therapy. The aim of this study is to explore the views of individuals with cryopreserved embryos on using human embryonic stem cells for treating PD. The study was performed as a qualitative, semi-structured interview study in June-October 2020. Participants were recruited at a private fertility clinic located in one of the larger Swedish cities. The clinic provides both publicly financed and privately financed IVF-treatments. All interviews were performed by telephone and analyzed using thematic content analysis. Five main categories emerged from 27 sub-categories. In total, 18 interviews were performed with 22 individuals, as either a couple (n = 16) or separately (n = 6). Participants had different views on what a cryopreserved embryo is. Some participants addressed cryopreserved embryos as 'a lump of cells', and some in terms of their 'unborn child'. Conditions for donation of cryopreserved embryos for cell-based treatment in PD were: not losing control of what is happening to the embryo, that donating must be voluntary and based on informed consent with time for reflection, that reimbursement, equality and transparency. Using cryopreserved embryos to treat PD is associated with fundamental ethical and practical issues. This study shows that IVF couples with left-over embryos may be supportive but there is a need for future research to assess people's views on using cryopreserved embryos for cell-based treatment in PD on a more aggregated level.
Sections du résumé
BACKGROUND
Parkinson's disease (PD) has been considered to be one of the most promising target diseases for forthcoming cell-based therapy. The aim of this study is to explore the views of individuals with cryopreserved embryos on using human embryonic stem cells for treating PD.
METHODS
The study was performed as a qualitative, semi-structured interview study in June-October 2020. Participants were recruited at a private fertility clinic located in one of the larger Swedish cities. The clinic provides both publicly financed and privately financed IVF-treatments. All interviews were performed by telephone and analyzed using thematic content analysis. Five main categories emerged from 27 sub-categories.
RESULTS
In total, 18 interviews were performed with 22 individuals, as either a couple (n = 16) or separately (n = 6). Participants had different views on what a cryopreserved embryo is. Some participants addressed cryopreserved embryos as 'a lump of cells', and some in terms of their 'unborn child'. Conditions for donation of cryopreserved embryos for cell-based treatment in PD were: not losing control of what is happening to the embryo, that donating must be voluntary and based on informed consent with time for reflection, that reimbursement, equality and transparency.
CONCLUSIONS
Using cryopreserved embryos to treat PD is associated with fundamental ethical and practical issues. This study shows that IVF couples with left-over embryos may be supportive but there is a need for future research to assess people's views on using cryopreserved embryos for cell-based treatment in PD on a more aggregated level.
Identifiants
pubmed: 36463154
doi: 10.1186/s12910-022-00864-y
pii: 10.1186/s12910-022-00864-y
pmc: PMC9719640
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
124Informations de copyright
© 2022. The Author(s).
Références
Stem Cell Rev Rep. 2020 Feb;16(1):3-32
pubmed: 31760627
CMAJ. 2016 Nov 1;188(16):1157-1165
pubmed: 27221269
Bosn J Basic Med Sci. 2021 Dec 01;21(6):672-701
pubmed: 34255619
BMC Med Ethics. 2022 Mar 4;23(1):15
pubmed: 35246133
Science. 1998 Nov 6;282(5391):1145-7
pubmed: 9804556
Br Dent J. 2008 Apr 26;204(8):429-32
pubmed: 18438371
J Parkinsons Dis. 2021;11(s2):S159-S165
pubmed: 33814467
Lancet Neurol. 2006 Jan;5(1):75-86
pubmed: 16361025
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7844-8
pubmed: 7544005
Prog Neurobiol. 2018 Sep;168:1-20
pubmed: 29653250
Cell Rep. 2019 Sep 24;28(13):3462-3473.e5
pubmed: 31553914
Br Med Bull. 2011;99:155-68
pubmed: 21669982
Endocr Rev. 2009 May;30(3):204-13
pubmed: 19366754
Nat Rev Genet. 2001 Jan;2(1):74-8
pubmed: 11253076
JBRA Assist Reprod. 2021 Apr 27;25(2):276-281
pubmed: 33565288
Cell Stem Cell. 2020 Oct 1;27(4):523-531
pubmed: 33007237
Am Fam Physician. 2020 Dec 1;102(11):679-691
pubmed: 33252908
JAMA. 2020 Feb 11;323(6):548-560
pubmed: 32044947
Hum Reprod. 2016 Jul;31(7):1508-14
pubmed: 27165623
Swiss Med Wkly. 2008 Sep 20;138(37-38):551-6
pubmed: 18803036
Hum Reprod. 2003 Jun;18(6):1353-5
pubmed: 12773471